论文部分内容阅读
目的:探讨选择不同方法终止瘢痕子宫14-20周妊娠引产表现出的有效性与安全性。方法:选取我院2010年05月—2014年05月瘢痕子宫妊娠(14周-20周),并且要求终止妊娠患者112例。利用随机数表法完成所有患者的随机分组。设为A1组(56例观察组)与A2组(对照组56例)。针对A1组患者,首先进行羊膜腔穿刺,对患者注射剂量为100毫克的依沙吖啶,之后选择剂量为75毫克的米非司酮(口服)给予临床治疗。每间隔12小时给药一次,2次/天。针对A2组患者,单纯选择依沙吖啶对患者实施羊膜腔内注射引产。结果:在患者引产时间等方面,A1组与A2组之间存在显著差异(P<0.05)。结论:针对瘢痕子宫中期终止妊娠引产患者,选择依沙吖啶+米非司酮给予临床治疗,获得的效果显著,具有广泛的临床应用价值。
Objective: To investigate the effectiveness and safety of different methods of termination of induced abortion in 14-20 weeks of uterine scar. Methods: Select our hospital from May 2010 to May 2014 scar pregnancy (14 weeks -20 weeks), and require termination of pregnancy in 112 patients. All patients were randomized using a random number table. Set to A1 (56 cases) and A2 (56 cases in control group). For group A1 patients, amniocentesis was performed first, patients were injected with ethacridine at a dose of 100 mg, and then mifepristone (oral) at a dose of 75 mg was given clinically. Administered every 12 hours, 2 times / day. For A2 patients, simply select ethacridine in patients with intra-amniotic injection of induced abortion. Results: There was a significant difference (P <0.05) between A1 group and A2 group in induction of labor. CONCLUSIONS: In the treatment of induced termination of pregnancy due to termination of pregnancy in mid-term hypertensive scar, it is of great value to choose ethacridine and mifepristone for clinical treatment and has a wide range of clinical value.